Nektar Therapeutics kündigt Phase-2b-Studie mit Rezpegaldesleukin bei atopischer Dermatitis an

Reuters

Feb 10

Nektar <a href="https://laohu8.com/S/LENZ">Therapeutics</a> kündigt Phase-2b-Studie mit Rezpegaldesleukin bei atopischer Dermatitis an

Nektar Therapeutics hat angekündigt, die Topline-Ergebnisse aus dem 36-wöchigen Erhaltungszeitraum der laufenden Phase-2b-Studie REZOLVE-AD mit dem Prüfpräparat Rezpegaldesleukin bei moderater bis schwerer atopischer Dermatitis vorzustellen. Die Präsentation der Ergebnisse erfolgt am 10. Februar 2026 im Rahmen eines Investoren-Calls und einer Live-Webübertragung. Die Ergebnisse werden am selben Morgen in einer Pressemitteilung veröffentlicht und im Anschluss auf der Unternehmenswebsite zur Verfügung gestellt.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF83914) on February 09, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610666953"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610666953\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610666953?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 05:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610666953","market":"fut","top_or_hot":-1,"title":"Nektar Therapeutics kündigt Phase-2b-Studie mit Rezpegaldesleukin bei atopischer Dermatitis an","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> kündigt Phase-2b-Studie mit Rezpegaldesleukin bei atopischer Dermatitis an\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nektar Therapeutics hat angekündigt, die Topline-Ergebnisse aus dem 36-wöchigen Erhaltungszeitraum der laufenden Phase-2b-Studie REZOLVE-AD mit dem Prüfpräparat Rezpegaldesleukin bei moderater bis schwerer atopischer Dermatitis vorzustellen. Die Präsentation der Ergebnisse erfolgt am 10. Februar 2026 im Rahmen eines Investoren-Calls und einer Live-Webübertragung. Die Ergebnisse werden am selben Morgen in einer Pressemitteilung veröffentlicht und im Anschluss auf der Unternehmenswebsite zur Verfügung gestellt.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF83914) on February 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar Therapeutics kündigt Phase-2b-Studie mit Rezpegaldesleukin bei atopischer Dermatitis an</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar Therapeutics kündigt Phase-2b-Studie mit Rezpegaldesleukin bei atopischer Dermatitis an\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-10 05:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> kündigt Phase-2b-Studie mit Rezpegaldesleukin bei atopischer Dermatitis an\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nektar Therapeutics hat angekündigt, die Topline-Ergebnisse aus dem 36-wöchigen Erhaltungszeitraum der laufenden Phase-2b-Studie REZOLVE-AD mit dem Prüfpräparat Rezpegaldesleukin bei moderater bis schwerer atopischer Dermatitis vorzustellen. Die Präsentation der Ergebnisse erfolgt am 10. Februar 2026 im Rahmen eines Investoren-Calls und einer Live-Webübertragung. Die Ergebnisse werden am selben Morgen in einer Pressemitteilung veröffentlicht und im Anschluss auf der Unternehmenswebsite zur Verfügung gestellt.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF83914) on February 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NKTR","symbol_name":"内克塔治疗","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL9mS2fv:1","article_id":"2610666953","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610666953","pubTimestamp":1770671764,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire  on February 09, 2026, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NKTR":"内克塔治疗","BK4007":"制药"},"translate_title":"Nektar Therapeutics宣布Rezpegaldesleukin治疗特应性皮炎的2b期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":0.9},"content_text":"Nektar Therapeutics kündigt Phase-2b-Studie mit Rezpegaldesleukin bei atopischer Dermatitis an\n    \n\n        Nektar Therapeutics hat angekündigt, die Topline-Ergebnisse aus dem 36-wöchigen Erhaltungszeitraum der laufenden Phase-2b-Studie REZOLVE-AD mit dem Prüfpräparat Rezpegaldesleukin bei moderater bis schwerer atopischer Dermatitis vorzustellen. Die Präsentation der Ergebnisse erfolgt am 10. Februar 2026 im Rahmen eines Investoren-Calls und einer Live-Webübertragung. Die Ergebnisse werden am selben Morgen in einer Pressemitteilung veröffentlicht und im Anschluss auf der Unternehmenswebsite zur Verfügung gestellt.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF83914) on February 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}